Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif. The Dana-Farber led research exemplifies innovative and multidisciplinary expertise in prostate, kidney, and bladder cancers, and includes studies examining novel treatments and predictive biomarkers.

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor treatment responses. Now, researchers from Japan have identified the transfer of mitochondria with mutated DNA from cancer cells to immune cells as a key mechanism of immune evasion and resistance to immunotherapy. Targeting this transfer could enhance the effectiveness of cancer immunotherapy.

Malignancy Spectrum, a cutting-edge journal dedicated to advancing the field of oncology, presents its latest issue, Volume 1, Issue 4.

This issue delves into the complex and multifaceted nature of cancer, offering a comprehensive exploration of the latest research, clinical findings, and innovative treatments. From the molecular underpinnings of tumor development to the latest breakthroughs in targeted therapies, this issue provides a platform for researchers, clinicians, and scientists to share their insights and discoveries. With a focus on basic and translational research, Malignancy Spectrum aims to bridge the gap between laboratory findings and clinical practice, ultimately improving patient outcomes and quality of life.

The results of their research were published in the journal Artificial Intelligence in Agriculture under the title “Neural network architecture search enabled wide-deep learning (NAS-WD) for spatially heterogenous property awared chicken woody breast classification and hardness regression.”